home / stock / ortx / ortx articles
NEW YORK, Oct. 08, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.1...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin...
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’...
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded down 0.15% ...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares rose 95.5% to $15.80 in pre-market trading after the company inked a deal with Kyowa Kirin...
Gene therapy company Orchard Therapeutics Plc (NASDAQ: ORTX) shares are trading higher after it agreed to be acquired by Kyowa Kirin...
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acq...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....